Balkhi Bander, Alqahtani Saeed, Altayyar Waad, Ghawaa Yazeed, Alqahtani Zuhair, Alsaleh Khalid, Asiri Yousif
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Saudi Pharm J. 2020 Jun;28(6):669-674. doi: 10.1016/j.jsps.2020.04.007. Epub 2020 Apr 25.
Drug utilization studies have proven to be an effective tool in the evaluation of rational drug use in different health care systems, including oncology. The drug utilization studies were used in many institutes to ensure the safe, effective and appropriate use of drugs being prescribed. The main aim of this study was to assess the utilization pattern of anticancer drugs in breast cancer patients.
A retrospective cross-sectional observational study was carried out at King Saud University Medical City (KSUMC) for 1 year from January 2016 to December 2016. All female patients diagnosed with breast cancer during this year were included in the study.
A total of 101 patients were included in this study. Most patients received an average of three anticancer drugs. The most commonly prescribed medication was fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen, which was used in 81% of patients. Combinations of FEC + docetaxel and FEC + docetaxel + trastuzumab were received by43% and 23% of patients, respectively. Docetaxel was the most commonly used drug in neoadjuvant setting, whereas letrozole and trastuzumab were prescribed more frequently in hormonal and targeted therapies, respectively. The total drug expenditure on anticancer therapy was approximately 3.8 million Saudi Riyals (S.R), with adjuvant therapy constituting over half of the total spending. In neoadjuvant settings, the spending cost for hormonal therapy was the highest. The condition of most breast cancer patients was improved during the study period, whereas only 29% of the included patients progressed.
FEC was the most common regimen used in this study, consistent with the National Comprehensive Cancer Network (NCCN) guideline recommendation. Our results indicated that adherence to a clinical guideline and recommended medication regimens improved patient outcomes. Our finding indicate how analyzing drug utilization pattern could benefit institutions in managing inventory and efficiently using health care resources.
药物利用研究已被证明是评估不同医疗保健系统(包括肿瘤学领域)合理用药的有效工具。许多机构开展药物利用研究以确保所开药物的安全、有效和合理使用。本研究的主要目的是评估乳腺癌患者抗癌药物的使用模式。
2016年1月至2016年12月在沙特国王大学医学城(KSUMC)进行了一项为期1年的回顾性横断面观察研究。该研究纳入了本年度所有诊断为乳腺癌的女性患者。
本研究共纳入101例患者。大多数患者平均接受三种抗癌药物。最常开具的药物方案是氟尿嘧啶、表柔比星和环磷酰胺(FEC)方案,81%的患者使用该方案。分别有43%和23%的患者接受了FEC + 多西他赛以及FEC + 多西他赛 + 曲妥珠单抗的联合用药。多西他赛是新辅助治疗中最常用的药物,而来曲唑和曲妥珠单抗分别在激素治疗和靶向治疗中更常被开具。抗癌治疗的总药物支出约为380万沙特里亚尔(S.R),辅助治疗占总支出的一半以上。在新辅助治疗中,激素治疗的花费最高。在研究期间,大多数乳腺癌患者的病情有所改善,而纳入的患者中只有29%病情进展。
FEC是本研究中最常用的方案,与美国国立综合癌症网络(NCCN)指南推荐一致。我们的结果表明,遵循临床指南和推荐的用药方案可改善患者预后。我们的研究结果表明分析药物使用模式如何能使机构在管理库存和有效利用医疗资源方面受益。